PRN Analgesia Leads to Expectations of Peak-and-Trough Pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

MADISON, Wis--An anomaly of pain management is that patients generally report satisfaction with their pain management, even though they are still experiencing pain. The downside of this finding is that if patients are truly satisfied, institutions may see no need to improve pain management programs.

MADISON, Wis--An anomaly of pain management is that patients generallyreport satisfaction with their pain management, even though theyare still experiencing pain. The downside of this finding is thatif patients are truly satisfied, institutions may see no needto improve pain management programs.

With that in mind, two researchers from the University of Wisconsin,Madison--Sandra E. Ward, PhD, RN, of the School of Nursing, andDebra B. Gordon, MS, RN, of the Hospital and Clinic--looked forthe reasons behind these high patient satisfaction ratings.

It may be that pain severity is generally less than patients expect,and so they are not dissatisfied. However, Dr. Ward offers a differenthypothesis. Since most patients receive analgesics "as needed,"she says, patients come to expect, and be satisfied with, a cyclicalpattern of pain relief. Thus, expectation of a pattern of painrelief rather than expectation of severity may be the most importantfactor in patient satisfaction.

Dr. Ward notes that most analgesics are still prescribed "asneeded," even though "around-the clock" schedulingis recommended by all pain management guidelines.

With "as needed" administration, patients experiencepain, ask for an analgesic, receive some level of pain relief,and then wait for the pain to return. In other words, they expect,and receive, a peak-and-trough pain cycle.

The issue was examined in a longitudinal study of patient satisfaction,measured at baseline and 2 years after implementation of a programto improve pain management (see table below). The protocol calledfor chart reviews and outpatient assessments via questionnairesand telephone interviews in an attempt to overcome the limitationsof the inpatient evaluations used for the baseline study.

For example, in the baseline study, nurses determined eligibility.If a nurse did not think a patient had pain, that patient wasnot asked to complete a survey. "The very patients most likelyto be dissatisfied with care may have been excluded from study,"Dr. Ward says. In addition, despite efforts to assure confidentiality,patients might have been hesitant to express dissatisfaction withthe people currently providing their care.

The results, reported in the April, 1996, issue of the Journalof Pain and Symptom Management (pp 242-251), showed little changefrom baseline in patient satisfaction with pain control, withthe vast majority reporting being satisfied or highly satisfied.Pain intensity ratings also showed little change.

The chart review showed that "as needed" rather than"scheduled" analgesic administration predominated: Only10 of 46 orders for IV analgesics specified patient-controlledanalgesia.

The investigators conclude that "patients may neither appreciatenor understand that scheduled around-the-clock dosing can providemore consistent pain relief by dampening peaks and allowing moretime at low pain intensities."

Steps Taken toImprove the Management of Pain at the University of Wisconsin

1. A Pain Resource Nurse program was begun in which nurses fromeach unit were trained to be resources in the care of patientswith pain.

2. Monthly interdisciplinary pain case conferences were established.

3. Nationally known pain management experts consulted with thepain team.

4. Flowsheets were revised to include pain triggers and spacefor documentation of pain assessments.

5. Pain was added to the standard nursing assessment parameters.

6. A laminated pain reference card was provided to nursing andmedical staff.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video